- Home
- ADGM vs EVAX Comparison
ADGM vs EVAX Comparison
Compare ADGM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- EVAX
- Stock Information
- Founded
- ADGM 2011
- EVAX 2008
- Country
- ADGM United States
- EVAX Denmark
- Employees
- ADGM N/A
- EVAX N/A
- Industry
- ADGM
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADGM
- EVAX Health Care
- Exchange
- ADGM NYSE
- EVAX Nasdaq
- Market Cap
- ADGM 14.7M
- EVAX 16.3M
- IPO Year
- ADGM N/A
- EVAX 2021
- Fundamental
- Price
- ADGM $1.11
- EVAX $1.49
- Analyst Decision
- ADGM
- EVAX Strong Buy
- Analyst Count
- ADGM 0
- EVAX 2
- Target Price
- ADGM N/A
- EVAX $10.00
- AVG Volume (30 Days)
- ADGM 6.0M
- EVAX 76.2K
- Earning Date
- ADGM 05-15-2025
- EVAX 05-27-2025
- Dividend Yield
- ADGM N/A
- EVAX N/A
- EPS Growth
- ADGM N/A
- EVAX N/A
- EPS
- ADGM N/A
- EVAX N/A
- Revenue
- ADGM $602,000.00
- EVAX $3,344,000.00
- Revenue This Year
- ADGM N/A
- EVAX $102.45
- Revenue Next Year
- ADGM N/A
- EVAX $100.30
- P/E Ratio
- ADGM N/A
- EVAX N/A
- Revenue Growth
- ADGM 100.67
- EVAX 4480.82
- 52 Week Low
- ADGM $0.63
- EVAX $1.20
- 52 Week High
- ADGM $9.34
- EVAX $21.80
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- EVAX 43.19
- Support Level
- ADGM N/A
- EVAX $1.20
- Resistance Level
- ADGM N/A
- EVAX $1.46
- Average True Range (ATR)
- ADGM 0.00
- EVAX 0.13
- MACD
- ADGM 0.00
- EVAX 0.03
- Stochastic Oscillator
- ADGM 0.00
- EVAX 59.18
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.